|Based on the declarations required by law and by the by-laws received by the Company, its shareholding structure is:|
|Main shareholders||Bpifrance Participations SA (ex FSI): 1.54% , HBM Partners: 5.82%|
|Share capital||€29 588 510|
|Number of outstanding shares||29 588 510|
|Number of voting rights as of May 31, 2018||29 588 510|
|Total number of voting rights calculated on the basis of all the shares to which voting rights are attached even if exercise thereof is suspended||29 588 510|
|Reverse stock split||Notice published in the BALO on October 19,2015 (in French) Frequently asked questions|
|Termination of the liquidity agreement with Gilbert Dupont|
|Eligibility PEA/PME 2017-2018 (document in French)|
|Euroclear France code||7413|
|NYSE Euronext||CAC Mids & Smalls|
|FTSE Classification||Economical group: non cyclical consumer goods (40) Industrial sector: pharmaceuticals (48) Industry sub-sector: pharmaceuticals (480)|
|Listing Segment||Euronext Paris: Eurolist Next Economy|
The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.
|(in K€)||As of December 31, 2017||As of December 31, 2016|
|Cash & Cash Equivalents||41,394||28,859|
|Other current assets||2,897||1,833|
|TOTAL ASSETS||152, 252||148,748|
|TOTAL EQUITY AND LIABILITIES||152,252||148,748|
Cash, cash equivalents as of March 31, 2018: €36.3 million
|(in K€)||As of December 31, 2017||As of December 31, 2016|
|Pfizer royalties payment*||(12,775)||–|
|Non operating income/ (expenses)||10,221***||1,045|
|LOSS FROM CONTINUING OPERATIONS||(8,297)||(6,742)|
|Loss from discontinued operations||4,678||(12,293)|
|NET LOSS OF THE YEAR||(3,619)||(19,035)|
*includes a milestone and royalties **included non-cash impacts of the change in value of potential earn-out payable in shares to Nicox Ophthalmics Inc. former shareholders, (984K€) for 2017 and 12,741 k€ for 2018 ***included non-cash impact of the reduction of deferred tax liability related to Nicox Ophthlamics Inc. following the new US tax law voted in December 2017
|2017 Year-end results||March 6, 2018|
|2018 First-Half results||September 2018|
|2018 First Quarter||May 4, 2018|
|2018 Second Quarter||July 2018|
|2018 Third Quarter||October 2018|
|May 4, 2018||First Quarter 2018 Business and Financial Results|
|October 24, 2017||Third quarter 2017 business update and cash position|
|September 8, 2017||First half 2017 business and financial update|
|April 27, 2017||First quarter 2017 business update and cash position|
|March 31, 2017||2016 Financial results – Press release and Presentation|
|October 11, 2016||Third quarter 2016 business update and cash position|
|September 22, 2016||First half 2016 financial update|
|May 10, 2016||First quarter 2016 financial results|
|April 15, 2016||2015 Financial results Press release and Presentation and Audiorecording|
The documents listed below are available in PDF
Private Placement Reserved for a Category of Investors 2017
Private Placement Reserved for a Category of Investors 2016
Share capital increase, 2015
|Note d’opération||Visa n°15-080 granted by the AMF on March 6. 2015. In French.|
|Second update of the 2013 Annual Report (Document de référence)||Submission to the AMF on March 6, 2015. In French.|
Private placement and Rights issue, 2009
|Note d’opération||Visa n°09-347 on November 24, 2009. In French.|
|Résumé du prospectus||November 24, 2009. In French.|
|Update of the Financial Prospectus 2008||Submission to the AMF on November 17, 2009. In French.|
Rights issue, 2007
|Note d’opération||visa n°07-021 granted by the AMF on January 18, 2007, regarding the offering of new ordinary shares in a global offering (these new shares were initially offered by way of listed and transferable preferential subscription rights allocated to shares held by the Company’s existing shareholders). In French.|
|Summary of the prospectus||January 18, 2007. In French.|
|Update of the Financial Prospectus 2005||Submission to the AMF under the number D.06-140-A01 on January 18, 2007. In French.|
Private placement, 2006
|Communiqué||visa n°06-132 granted by the AMF on May 3, 2006. In French.|
|Note d’opération||May 3, 2006; regarding the listing on the Eurolist of Euronext Paris of new shares issued following an increase in share capital reserved for certain categories of investors, with suppression of the shareholders preferential right of subscription. In French.|
Private placement, 2004
|Communiqué||visa n°04-811 granted by the AMF on October 4, 2004. In French.|
|Note d’opération||October 4, 2004; regarding the listing on the Nouveau Marché of Euronext Paris of new shares issued following an increase in share capital reserved for certain categories of investors, with suppression of the shareholders preferential right of subscription. In French.|
Rules and regulations of the Board of Directors
The Board of Directors of the Company has adopted rules and regulations to govern its functioning and that of its committees. These rules and regulations have been updated on May 16, 2018. The rules and regulations of the Board of Directors notably include provisions on the following points:
- Composition of the Board of Directors, in order to ensure and control its independence. At least two Company’s Board members must be, to the extent possible, independent. The independence of Board members must be assessed each year by the Board based on the criteria provided for in the MiddleNext Governance code.
- Holding of Board meetings. Subject to the limits and exceptions provided for by law, are deemed to attend Board meetings, with respect to quorum and majority, Board members taking part in the meeting by means of Visio conference or telecommunication which enable their identification and effective participation. These means of participation are that allowed by applicable regulations and shall be used under the conditions permitted by law. Specifically, participation by means of Visio conference or telecommunication is not permitted for meetings on the review of the statutory and consolidated financial annual returns or for the approval of the management report.
- Information of the Board members. Board members must be given regular information on the financial situation of the Company, its cash position and financial commitments. The Chairman must communicate to the Board members any significant piece of information regarding the Company. All Board members are entitled to receive any piece of information or any document that any member considers necessary for the performance of his duties. Board members are further entitled to meet any member the Company’s management, outside the presence of the Chairman.
- Decisions for which the Chief Executive Officer must obtain preliminary authorization of the Board. The list of such decisions notably include: decisions to set up new offices abroad or to close down these offices; significant operations that could affect the Group’s strategy or alter its financial structure or its scope of activity; buying or selling of shares from other companies; any transactions concerning goods, titles or shares; buying or selling real estate; the granting of securities on assets of the Company of the obtaining of loans exceeding € 150,000.
- Designation and functions of the committees. The Board may set up committees among its members to prepare the Board’s work. The Board fixes the functions of each committee; the committees work under the exclusive and collective responsibility of all Board members. The Committees help prepare the decisions to be made by the Board by making recommendations and giving advice. Committee members must personally attend the meetings and cannot be represented by another member. Committees can only meet when half of the committee members attend. The committees can choose to discuss any item within their field of competence. They may also be seized by the Board or its Chairman.
- Attributions of the Audit Committee. The attributions of the Audit Committee include ensuring the quality of internal control and the reliability of information provided to shareholders and to the financial markets. The Audit Committee is notably in charge of following the process of preparation of the financial information, of monitoring the efficacy of internal control systems (evaluation of the internal control procedures, review of proposed internal audits and implementation of the recommendations prepared based on the outcome of internal audits, evaluation of risk assessment), of following the legal control of statutory and consolidated accounts by the Statutory Auditors (review of the assumptions used for the preparation of the accounts, review of the annual, half yearly and, as the case may be, quarterly statutory and consolidated accounts before their submission to the Board, review with the Statutory Auditors of the relevance and implementation of the accountancy principles utilized, review of major transactions for which a potential conflict of interest could arise), of ensuring the independence of the Statutory Auditors and following the procedure of their selection, their fees; and the recourse to the Statutory Auditors for any missions other than the audit of accounts.
- Composition of the Audit Committee. The Audit Committee counts three to five members. It is composed of independent members, to the extent possible, for at least two thirds of its members and comprises at least one member with financial or accountancy competences. The Chairman&CEO is in principle not member of the Audit committee. The Audit Committee meets as often as it deems necessary and at least twice a year prior to the Board meetings called to review the yearly and half-yearly accounts. The Committee may request from the Chairman the communication of all documents or the audition of all persons. The Committee must receive a summary of the internal audit reports, and may have recourse to external experts.
- Attributions of the Compensation Committee. The attributions of the Compensation Committee consist in making proposals on the general remuneration policy of the corporate officers (fixed and variable, benefits in kind, retirement, severance packages) and for the allocation of free shares, stock-options and warrants; in making recommendations regarding the remuneration package of each corporate officer (including benefits in kind); in making proposals regarding the global amount of the director fees and their allocation between Board members; in making proposals regarding the remuneration package (including stock-options and free shares) of the management team (Senior Directors, Vice-Presidents, Chief Financial Officer); in examining a proposed consolidated yearly salary raise; in reviewing the contemplated stock-option and free share attributions to employees and the criteria of attribution and conditions applicable to the attributions; in collecting information regarding the remuneration and benefits in kind paid to the corporate officers of the Company and of the controlled entities of the Goup.
- Composition of the Compensation Committee. The Committee counts three to five members. It is composed, whenever possible, for at least half of its members, of Board members considered as independent. The Chairman & CEO is in principle not member of the Compensation Committee. The Committee meets as often as it deems necessary and at least once a year. The Committee may request from the Chairman the communication of all documents or the audition of all persons.
- Attributions of the Corporate Governance Committee. The attributions of the Corporate Governance Committee consist in evaluating the efficacy and adequacy of corporate governance procedures; submitting recommendations to improve good corporate governance within the Company; making proposals regarding the composition of the Committees and their attributions; examining candidacies of potential Board members and for the strategic managerial functions, examining the social, societal and environmental consequences of the Company’s activities and strategy.
- Composition of the Corporate Governance Committee. The Corporate Governance Committee counts three to five members. At least half of its members should, to the extent possible, be considered as independent. The Chairman & CEO is in principle not member of the Corporate Governance Committee but participates in the selection of proposed Board members and other corporate officers. The Committee may request from the Chairman the communication of all documents or the audition of all persons.
- Attributions of the Science and Technology Committee. The Science and Technology Committee aims to assist the Board in the general oversight of the scientific and technical aspects of the Company’s business and periodically report to Board.
Its main attributions are as follows:
a. Assist the Board in its general oversight of R&D program goals and objectives by reviewing management’s progress and performance in achieving goals and objectives and mitigating associated risks;
b. Review the Company’s research pipeline;
c. Review and advise the Board on the scientific, technical and medical aspects of transactions that require Board approval;
d. Identify significant new and emerging trends and developments in R&D and science and their potential impact on the Company;
e. Review the Company’s intellectual property portfolio and strategy;
f. Perform any other activities and functions as the Committee deems necessary or appropriate to carry out its responsibilities to assist the Board in its oversight of the Company’s R&D activities;
g. Annually review the adequacy of these attributions and submit proposed changes to the Board for approval;
h. Conduct an annual self-evaluation of the Committee’s performance.
- Composition of the Science and Technology Committee. The Committee is composed of minimum two and maximum five Board members and, whenever possible, of Board members considered as independent. In principle, the Chairman of the Board, the General Manager and the Delegate General Managers shall not be members of the Science and Technology Committee. However, the Chairman of the Board may participate in the meetings of the Science and Technology Committee upon request of its members. The Committee meets as often as it deems necessary and at least three times a year and fixes the calendar of its meetings. It may also meet at the request of two of its members, of its Chairman or of the Chairman of the Board. The Committee may, for the accomplishment of the tasks it is entrusted with, request from the Chairman the communication of all documents or the audition of all persons
- Principles for the allocation of director fees. The Board may notably take into account, for such allocation, attendance to Board meetings and participation in the Committees.
- Reminder of confidentiality obligations.
- Reminder of the legal obligation for shares held by Board members to be in registered form.
- Procedure for the declaration of transactions made by Board members and their families on the Company’s shares providing that Board members, and General Managers (CEO) must declare in writing to the French ‘Autorité des Marchés Financiers’ (AMF),under the formalities required from time to time, all transactions on Company shares made by themselves or by one of their relatives.
Recommendations to prevent insider trading
The Board has adopted, aimed at its employees and corporate officers, recommendations to prevent insider trading. These recommendations include a list of precautions to safeguard the secrecy of sensitive information. Publication of the deferred remuneration of the Chairman and Chief Executive Officer – in French